Compounds > 2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1h-inden-1-one
Page last updated: 2024-12-11

2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1h-inden-1-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one: a Dusp6 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5475586
CHEMBL ID2010464
SCHEMBL ID3698122
SCHEMBL ID3705322
MeSH IDM0539105

Synonyms (16)

Synonym
(2z)-2-benzylidene-3-(cyclohexylamino)-3h-inden-1-one
BRD-A11007541-003-01-9
SCHEMBL3698122
SCHEMBL3705322
AKOS021726966
CHEMBL2010464
2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1h-inden-1-one
(2z)-3-(cyclohexylamino)-2-(phenylmethylidene)-2,3-dihydro-1h-inden-1-one
15982-84-0
EX-A3815
BS-16023
HY-126390
(e/z)-bci
CS-0103275
(e/z)-bci(dusp6 inhibitor)
AKOS037648917
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's2 (25.00)24.3611
2020's5 (62.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.05 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Prostate
[description not available]		02.3110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.3110
Cerebral Infarction, Middle Cerebral Artery
[description not available]		02.110
Acute Brain Injuries
[description not available]		02.110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.110
Brain Inflammation
[description not available]		02.110
Brain Injuries
Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.		02.110
Encephalitis
Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.		02.110
Infarction, Middle Cerebral Artery
NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.		02.110
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.0710